Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Holdings in Moderna, Inc. $MRNA

Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 2.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 158,130 shares of the company’s stock after purchasing an additional 4,208 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Moderna were worth $4,399,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new position in Moderna in the 1st quarter worth about $25,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Moderna during the second quarter valued at about $26,000. TD Private Client Wealth LLC boosted its stake in Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after acquiring an additional 743 shares in the last quarter. Whittier Trust Co. purchased a new position in Moderna during the 2nd quarter worth $28,000. Finally, SVB Wealth LLC acquired a new position in shares of Moderna during the first quarter valued at about $28,000. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on MRNA. Morgan Stanley lifted their price target on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. UBS Group cut their price objective on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, October 23rd. Leerink Partners decreased their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. Bank of America dropped their price target on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, November 10th. Finally, Citigroup decreased their target price on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus target price of $35.85.

Moderna Stock Performance

Shares of MRNA opened at $24.77 on Friday. Moderna, Inc. has a 1 year low of $23.04 and a 1 year high of $48.92. The stock has a market capitalization of $9.68 billion, a PE ratio of -3.07 and a beta of 2.02. The stock has a 50-day simple moving average of $25.92 and a 200-day simple moving average of $27.07.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. Moderna’s revenue for the quarter was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. Analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.